Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives. We are committed to advancing the field of adeno-associated virus (AAV) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production.
February 12, 2014
Third Rock Ventures Launches Voyager Therapeutics with $45 Million Series A to Develop Life-Changing Gene Therapies for CNS Disorders